14/25 (56%) patients reached a minimum of 30% decrease of PSMA-positive tumour volume after a maximum of two cycles of ALCT (range − 100 to -46.5%) (Figs. 2), 3/25 (12%) patients were stable with tumour volumes between − 10.5% and + 10.5% and 8/25 (28%) patients had a significant increase in PSMA-positive tumour volume (range + 43% to + 398%) (Supplement 3). The gene discussed is FOLH1; the disease is neoplasm.